M2e: Phase I data

A double-blind, dose-escalating Phase I trial in 60 healthy volunteers showed that M2e was well tolerated and demonstrated immunogenicity at 0.3 µg dose. Subjects received 2 doses of 0.3, 1, 3 and 10 ...